Impact of human leucocyte antigen class II polymorphism on anti‐red blood cell antibody development: Correlations and indications
Vox Sanguinis · 2024
DOI: 10.1111/vox.13632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Milanka Milosavić und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Molecular Immunohematology, Institute for Transfusion Medicine of Republika Srpska, Banja Luka, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: HLA-DQ beta-Chains, Polymorphism, Genetic, HLA-DRB1 Chains, Isoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Government of Republika Srpska.
Abstract (Originalsprache)
Backround and Objectives Blood transfusion therapy is vital for many patient groups. They can cause many complications, and the development of anti‐red blood cell (RBC) antibodies is of significant importance. Molecules of class II human leucocyte antigens (HLA) are one of the several factors that influence antibody development in patients. Materials and Methods In this study, we investigated 108 patients who developed antibodies against different erythrocyte antigens and 115 patients on multiple transfusion therapies who did not develop anti‐RBC antibodies. The HLA loci HLA‐DRB1 and HLA‐DQB1 were typed using commercial molecular assays routinely used in HLA laboratories.
Results
An increased frequency of the HLA‐DRB1*04 allele group was observed in patients who developed antibodies. Additionally, HLA‐DRB1*09 was also significant for anti‐E development and in patients with multi‐specific alloimmunization. It was found that the HLA‐DRB1*07 allele group is associated with antibodies to antigents of the Rh and MNS systems but also lacks an association with anti‐K development. The HLA‐DRB1*11 and ‐DRB1*01 allele groups displayed a protective mechanism for anti‐E development, similar to that of HLA‐DQB1*02 for anti‐K.
Conclusion
There is an association between various HLA class II alleles and anti‐RBC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory for Molecular Immunohematology, Institute for Transfusion Medicine of Republika Srpska, Banja Luka, Bosnia and Herzegovina.
- Department of Biology, University of Osijek, Osijek, Croatia.
- Tissue Typing Department, Blood Transfusion Institute of Serbia, Belgrade, Serbia.
ORCID-Profile: Marko Lilić
Förderung
- Government of Republika Srpska
Zitieren
APA
Milosavić, M., Lilić, M., & Andrić, Z. (2024). Impact of human leucocyte antigen class II polymorphism on anti‐red blood cell antibody development: Correlations and indications. Vox Sanguinis. https://doi.org/10.1111/vox.13632
Vancouver
Milosavić M, Lilić M, Andrić Z. Impact of human leucocyte antigen class II polymorphism on anti‐red blood cell antibody development: Correlations and indications. Vox Sanguinis. 2024. doi:10.1111/vox.13632
BibTeX
@article{Milosavi2024,
author = {Milosavić, Milanka and Lilić, Marko and Andrić, Zorana},
title = {Impact of human leucocyte antigen class II polymorphism on anti‐red blood cell antibody development: Correlations and indications},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13632}
}
EUVIMED